Antigen | Clone | Isotype | Fluorochrome | Labeling strategy | Source of primary Ab |
---|---|---|---|---|---|
Phenotyping of moDCs | |||||
CD1 | 76-7-4 | IgG2a | Alexa647 | secondary antibodya | in housej |
CD14 | CAM36A | IgG1 | BV421 | secondary antibodyb | VMRD |
CD80/86 | CD152/Fc chimera | IgG2a | Alexa647 | secondary antibodya | Sigma-Aldrich |
CD163 | 2A10/11 | IgG1 | PE | directly conjugated | AbD Serotec |
CD169 | 3B11/11 | IgG1 | BV421 | secondary antibodyb | AbD Serotec |
CD172a | 74-22-15A | IgG2b | Alexa488 | secondary antibodyc | in housej |
SLA-DR | MSA3 | IgG2a | Alexa647 | secondary antibodya | in housek |
Assessment of moDC infection rate | |||||
CD172a | 74-22-15A | IgG2b | PE | secondary antibodyd | in housej |
PRRSV-N | P10/b1 | IgG1 | Alexa488 | directly conjugatede | in housel |
CD163, CD169, SLA-DR and CD80/86 expression on infected moDCs | |||||
CD172a | 74-22-15A | IgG2b | Alexa647 | secondary antibodyf | in housej |
SLA-DR | MSA3 | IgG2a | PE | directly conjugatedg | in housek |
CD80/86 | hCTLA4/Fc chimera | IgG2a | BV421 | two step biotin-streptavidinh | Sigma-Aldrich |
CD163 | 2A10/11 | IgG1 | PE | directly conjugated | AbD Serotec |
CD169 | 3B11/11 | IgG1 | BV421 | two step biotin-streptavidini | AbD Serotec |
PRRSV-N | P10/b1 | IgG1 | Alexa488 | directly conjugatede | in housel |